About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Gabapentin Treatment of Alcohol Dependence | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 2NCT00391716

Gabapentin Treatment of Alcohol Dependence

Gabapentin treatment for alcohol dependence

Lead sponsor: The Scripps Research Institute•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

The Scripps Research Institute

Collaborators

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

This is a 12-week, double blind, placebo controlled, dose ranging study to evaluate the efficacy of gabapentin in treating outpatients with alcohol dependence. Subjects receive 900mg or 1800mg gabapentin or placebo daily for 12 weeks accompanied by weekly standardized counseling for alcohol-related behavior, with assessments of alcohol consumption, mood, sleep and alcohol-craving performed each week.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Men and women over age 18 with alcohol dependence

Exclusion Criteria

•Currently meets Diagnostic and Statistical Manual 4 Text Revision (DSM-IV-TR) criteria for dependence on illicit substances
•Significant medical disorders that will increase potential risk or interfere with study participation
•Women with childbearing potential who are pregnant, nursing, or refuse to use a reliable method of birth control
•Treatment with an investigational drug in the last month.

Related studies

Transcranial Magnetic Stimulation (TMS) Effects Using Magnetoencephalography (MEG) Study

NCT06770556 · Alcohol Use Disorder, Alcohol Dependence, and more

SMART-r: Substance Monitoring and Active Relapse Tracking Repository

NCT06676059 · Alcoholism, Substance-Related Disorders

RECRUITINGPhase 2

Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder

NCT06939088 · Alcohol Use Disorder, Alcohol Abuse/Dependence, and more

Alcohol Misuse Treatment to Patients Newly Diagnosed With Alcohol-related Liver Disease: a Randomized Controlled Trial

NCT06493773 · Liver Diseases, Alcoholic, Alcohol Use Disorder, and more

Virtual Incentive Treatment for Alcohol

NCT06265506 · Alcohol Use Disorder, Alcohol Drinking, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 10, 2014Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment150

Start dateFeb 2004

Last updatedNov 10, 2014

Condition

Alcoholism Alcohol Dependence

Locations shown

The Scripps Research Institute

La Jolla, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 10, 2014Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions